Medical cannabis sales in Arkansas fell 2.6% during the first six months of 2026, compared to the same period a year earlier, according to Department of Finance and State Administration (DFA) data outlined by Talk about Business and Politics. During the first six months of this year, sales of medical cannabis in the state reached $140.3 million, compared to $144 million during the first half of 2025.

The DFA said it collected $16.8 million in cannabis-derived tax revenue during the first half of the year, which includes revenue from a 6.5% sales tax and a 4% privilege tax on cannabis sales. Despite the drop in sales from January to June, the tax revenue matches the total collected by the agency from cannabis sales during the first six months of 2025, the report said. DFA spokesman Scott Hardin told TB&P that the totals could be the same despite lower sales “because of a large payout in an audit or some other factor,” adding that “tax revenue doesn’t always match sales data.”

Natural Help Dispensary in Sherwood led the state with 8.55% of total cannabis sales, followed by Suite 443 in Hot Springs with 8.02% of total sales; CROP Dispensary in Jonesboro with 5.33% of total sales; Harvest Dispensary in Conway with 5.32% of total sales; and Custom Cannabis in Alexander with 4.43% of total sales.

According to Health Department data outlined by TB&P, there are 119,074 active medical cannabis patient cards in the state, a 7.7% increase over July 2025.

Ganjapreneur: Providing everyday knowledge since 2014, the leading digital business magazine for cannabis industry professionals. Subscribe to the newsletter to join our community of over 40,000 cannabis entrepreneurs.

The Wyoming Attorney General’s Office said the state will not reschedule cannabis under state law, regardless federal reforms the movement of medical cannabis from Schedule I to Schedule III under the Controlled Substances Act. In a policy statement released last week, the attorney general’s office said the state has already scheduled Food and Drug Administration (FDA)-approved pharmaceutical cannabis drugs — such as Dronabinol and Cesamet — as Schedule III and Schedule II drugs, respectively, and that Epidiolex has been completely removed from the state’s drug schedule.

The ruling states that state lawmakers have not legalized cannabis for any purpose in the state or recognized any other state’s medical cannabis licenses.

“Therefore, placing marijuana subject to a state medical marijuana license in Schedule III of the Wyoming Controlled Substances Act is inconsistent with the police powers heretofore exercised by the Wyoming Legislature. – Wyoming Attorney General’s Office, “Final Decision of the Commissioner of Drug and Substance Control Regarding the Placement of FDA-Approved Drug Products Containing Marijuana and Marijuana Under State License in Schedule III of the Wyoming Substances Act,” 7/7/26

The announcement adds that during a hearing in June regarding potential state rescheduling of cannabis, eight comments were received from the Drug and Substance Abuse Commissioner. Comments were evenly split between maintaining the status quo and rescheduling cannabis in Schedule III.

The order states that the commissioner “shall appropriately schedule products approved by the (FDA) after that agency has approved the product.”

Ganjapreneur: Providing everyday knowledge since 2014, the leading digital business magazine for cannabis industry professionals. Subscribe to the newsletter to join our community of over 40,000 cannabis entrepreneurs.